莫西沙星治疗急性细菌性鼻窦炎疗效与安全性的Meta分析

发布时间：2018-06-21 04:39

本文选题：莫西沙星 + 急性细菌性鼻窦炎　；参考：《中国医院药学杂志》2014年23期

【摘要】：目的:系统评价莫西沙星治疗急性细菌性鼻窦炎(ABS)的疗效和安全性。方法:计算机检索英文数据库Pubmed、Embase、the Cochrane Library、Medline和中文数据库CBM、CNKI、VIP和万方数据库,并手工检索相关会议论文集和灰色文献等,纳入莫西沙星治疗急性细菌性鼻窦炎的随机对照试验(RCT)。检索时限均从各数据库建库至2013年6月。按照纳入与排除标准选择文献、评价质量及提取资料后,采用RevMan5.2软件进行Meta分析。结果:共纳入5个RCTs,2 453例患者。Meta分析结果显示:PP分析中,莫西沙星组与其他抗菌药物组治疗ABS的临床有效率有统计学意义[RR=1.03,95%CI(1.00,1.05),P=0.04];而ITT分析中,2组治疗ABS的临床有效率无统计学意义[RR=0.99,95%CI(0.96,1.03),P=0.72]。PP分析中,莫西沙星组治疗ABS细菌清除率为95.07%,其他抗菌药物组细菌清除率为90.57%,2组无统计学意义[RR=1.04,95%CI(0.97,1.11),P=0.24];ITT分析中,2组不良反应发生率无统计学意义[RR=1.09,95%CI(0.86,1.38),P=0.49]。结论:基于当前的临床证据,莫西沙星治疗ABS的临床有效性不优于其他抗菌药物,细菌清除率和安全性与其他抗菌药物相当。
[Abstract]:Objective: to evaluate the efficacy and safety of moxifloxacin in the treatment of acute bacterial sinusitis. Methods: the database Pubmedmedus Embase was searched by computer, the Cochrane Library Medline and the Chinese database, CBMN CNKI VIP and Wanfang database were searched by computer, and related papers and grey literature were searched by hand, which were included in the randomized controlled trial of moxifloxacin in the treatment of acute bacterial sinusitis. The time limit for searching all the databases was built to June 2013. According to the inclusion and exclusion criteria, the literature was selected, the quality and extraction data were evaluated, and meta-analysis was carried out with Revman 5.2 software. Results: a total of 2 453 patients with RCTsN were included. The results of Meta-analysis showed that: 1. The clinical effective rate of moxifloxacin group and other antimicrobial drugs group in treating ABS was statistically significant [RRN 1.0395 CI 1.001.001.05 P0. 04], while ITT analysis showed no statistical significance in the clinical efficacy of ABS treatment in group 2 [RRN 0.99 + 95 CI 0.961.03C: P0.72] .PP analysis showed that the clinical efficacy of moxifloxacin and other antimicrobial agents in the treatment of ABS was not significantly higher than that in the control group (P < 0.05), but no significant difference was found in the clinical efficacy of the two groups in ITT analysis. The bacterial clearance rate in moxifloxacin group was 95.07, while that in other antimicrobial drugs group was 90.577.There was no significant difference in the rate of adverse reactions in ITT analysis between the two groups [RRR1.04C95CI0.971.11P0.24] [RR1.0995CI0.861.38P0.49]. Conclusion: based on the current clinical evidence, the efficacy of moxifloxacin in the treatment of ABS is not superior to that of other antimicrobial agents, and the bacterial clearance and safety are similar to those of other antimicrobial agents.
【作者单位】：广州医科大学附属第二医院药学部;广州医科大学附属第一医院药学部;中山大学药学院;
【基金】：国家科技部“十二五”科技支撑项目(编号:2013BAI06B04)
【分类号】：R765.41

【参考文献】